lunedì, 15 luglio 2024
8 Ottobre 2018

FDA Grants Selinexor Priority Review for Multiple Myeloma

October 6, 2018 – The FDA has granted a priority review to a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the XPO1 inhibitor. The NDA is based on results from the phase IIb STORM trial, which examined the combination of selinexor and dexamethasone in patients with penta-refractory multiple myeloma. Updated data from the study … (leggi tutto)